Novo Nordisk Aktie
41,50
EUR
+1,37
EUR
+3,40
%
41,59
EUR
+1,70
EUR
+4,26
%
Novo Nordisk jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Novo Nordisk Aktie Analyse
| 11.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.06.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 05.06.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.06.20 | Novo Nordisk Neutral | UBS AG | |
| 21.05.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 14.05.20 | Novo Nordisk Neutral | UBS AG | |
| 14.05.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 13.05.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 13.05.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 11.05.20 | Novo Nordisk Neutral | UBS AG | |
| 07.05.20 | Novo Nordisk overweight | Barclays Capital | |
| 07.05.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 06.05.20 | Novo Nordisk buy | UBS AG | |
| 06.05.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.05.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 29.04.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 17.04.20 | Novo Nordisk buy | UBS AG | |
| 15.04.20 | Novo Nordisk buy | UBS AG | |
| 15.04.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 15.04.20 | Novo Nordisk Outperform | Bernstein Research | |
| 14.04.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 09.04.20 | Novo Nordisk overweight | Barclays Capital | |
| 07.04.20 | Novo Nordisk Hold | Deutsche Bank AG | |
| 07.04.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.04.20 | Novo Nordisk Hold | Deutsche Bank AG | |
| 31.03.20 | Novo Nordisk Neutral | Oddo BHF | |
| 24.03.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 23.03.20 | Novo Nordisk buy | UBS AG | |
| 18.03.20 | Novo Nordisk Outperform | Bernstein Research | |
| 17.03.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 17.03.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 17.03.20 | Novo Nordisk overweight | Barclays Capital | |
| 02.03.20 | Novo Nordisk overweight | Barclays Capital | |
| 25.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.02.20 | Novo Nordisk Hold | Deutsche Bank AG | |
| 06.02.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 06.02.20 | Novo Nordisk Neutral | UBS AG | |
| 06.02.20 | Novo Nordisk overweight | Barclays Capital | |
| 06.02.20 | Novo Nordisk Outperform | Bernstein Research | |
| 06.02.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 05.02.20 | Novo Nordisk overweight | Barclays Capital | |
| 05.02.20 | Novo Nordisk Outperform | Bernstein Research | |
| 05.02.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 05.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 31.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 29.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 27.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 22.01.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 20.01.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
Werbung
Werbung